These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28802754)

  • 1. Cost-benefit analyses of supplementary measles immunisation in the highly immunized population of New Zealand.
    Hayman DTS; Marshall JC; French NP; Carpenter TE; Roberts MG; Kiedrzynski T
    Vaccine; 2017 Sep; 35(37):4913-4922. PubMed ID: 28802754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis.
    Zimmermann M; Frey K; Hagedorn B; Oteri AJ; Yahya A; Hamisu M; Mogekwu F; Shuaib F; McCarthy KA; Chabot-Couture G
    Vaccine; 2019 Sep; 37(41):6039-6047. PubMed ID: 31471147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measles vaccination in an increasingly immunized and developed world.
    Hayman DTS
    Hum Vaccin Immunother; 2019; 15(1):28-33. PubMed ID: 30156949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo.
    Doshi RH; Eckhoff P; Cheng A; Hoff NA; Mukadi P; Shidi C; Gerber S; Wemakoy EO; Muyembe-Tafum JJ; Kominski GF; Rimoin AW
    Vaccine; 2017 Oct; 35(45):6187-6194. PubMed ID: 28966000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measles control in developing and developed countries: the case for a two-dose policy.
    Tulchinsky TH; Ginsberg GM; Abed Y; Angeles MT; Akukwe C; Bonn J
    Bull World Health Organ; 1993; 71(1):93-103. PubMed ID: 8440043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The average cost of measles cases and adverse events following vaccination in industrialised countries.
    Carabin H; Edmunds WJ; Kou U; van den Hof S; Nguyen VH
    BMC Public Health; 2002 Sep; 2():22. PubMed ID: 12241559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost saving opportunity of introducing a card review into measles-containing vaccination campaigns.
    Hagedorn BL; Dabbagh A; McCarthy KA
    Vaccine; 2019 Sep; 37(41):6093-6101. PubMed ID: 31471145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001.
    Zhou F; Santoli J; Messonnier ML; Yusuf HR; Shefer A; Chu SY; Rodewald L; Harpaz R
    Arch Pediatr Adolesc Med; 2005 Dec; 159(12):1136-44. PubMed ID: 16330737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic analysis of the current universal 2-dose measles-mumps-rubella vaccination program in the United States.
    Zhou F; Reef S; Massoudi M; Papania MJ; Yusuf HR; Bardenheier B; Zimmerman L; McCauley MM
    J Infect Dis; 2004 May; 189 Suppl 1():S131-45. PubMed ID: 15106102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of heterogeneity in uptake of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling study.
    Glasser JW; Feng Z; Omer SB; Smith PJ; Rodewald LE
    Lancet Infect Dis; 2016 May; 16(5):599-605. PubMed ID: 26852723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of an intervention project engaging Traditional and Religious Leaders to improve uptake of childhood immunization in southern Nigeria.
    Oyo-Ita AE; Hanlon P; Nwankwo O; Bosch-Capblanch X; Arikpo D; Esu E; Auer C; Meremikwu M
    PLoS One; 2021; 16(9):e0257277. PubMed ID: 34529714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased measles-mumps-rubella (MMR) vaccine uptake in the context of a targeted immunisation campaign during a measles outbreak in a vaccine-reluctant community in England.
    Le Menach A; Boxall N; Amirthalingam G; Maddock L; Balasegaram S; Mindlin M
    Vaccine; 2014 Feb; 32(10):1147-52. PubMed ID: 24440207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.
    Ginsberg GM; Tulchinsky TH
    J Epidemiol Community Health; 1990 Dec; 44(4):274-80. PubMed ID: 2126028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the Auckland 2014 measles outbreak indicates that adolescents and young adults could benefit from catch-up vaccination.
    Reynolds G; Dias C; Thornley S; King R; Morrison A; Matson A; Hoskins R
    N Z Med J; 2015 Sep; 128(1422):53-62. PubMed ID: 26411847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Estimate of the cost/benefit ratio of measles vaccination].
    Cárdenas Ayala VM; Ruiz Matus C; Cabrera Coello L; Montesano Castellanos R; Garrido Lozada MT; Olvera Castillo R; Díaz Ortega JL
    Salud Publica Mex; 1989; 31(6):735-44. PubMed ID: 2516660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles immunity gaps and the progress towards elimination: a multi-country modelling analysis.
    Trentini F; Poletti P; Merler S; Melegaro A
    Lancet Infect Dis; 2017 Oct; 17(10):1089-1097. PubMed ID: 28807627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness evaluation of measles immunization strategies on a college campus.
    Shlian DM; Matchar D; Seymann GB
    Fam Pract Res J; 1991 Jun; 11(2):193-207. PubMed ID: 1905455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination for tomorrow: the need to improve immunisation rates.
    Kassianos G
    J Fam Health Care; 2010; 20(1):13-6. PubMed ID: 20397551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.